|
|
Volumn 9, Issue 1-2, 2001, Pages 63-70
|
|
Etodolac (Lodine®): Profile of an established selective COX-2 inhibitor
|
|
Author keywords
COX 2; Etodolac; NSAIDs
|
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
DICLOFENAC;
ETODOLAC;
IBUPROFEN;
INDOMETACIN;
NAPROXEN;
PIROXICAM;
PLACEBO;
PROSTAGLANDIN;
PROSTAGLANDIN SYNTHASE;
TENOXICAM;
ANTIINFLAMMATORY ACTIVITY;
CHRONIC DISEASE;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIGESTIVE SYSTEM PERFORATION;
DIGESTIVE SYSTEM ULCER;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERANCE;
ENZYME INHIBITION;
GASTROINTESTINAL HEMORRHAGE;
HIGH RISK POPULATION;
HUMAN;
MAJOR CLINICAL STUDY;
PRIORITY JOURNAL;
PROSTAGLANDIN RELEASE;
RANDOMIZED CONTROLLED TRIAL;
RHEUMATOID ARTHRITIS;
THEORY;
|
|
EID: 0034943335
PISSN: 09254692
EISSN: None
Source Type: Journal
DOI: 10.1163/156856001300248335 Document Type: Conference Paper |
|
Times cited : (12)
|
|
References (30)
|
